Sino Biopharmaceutical (HK:1177) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical has entered into a global collaboration with Biosion and Aclaris Therapeutics to develop an anti-TSLP monoclonal antibody, BSI-045B. Aclaris will pay over $40 million in cash and 19.9% in common stock to Sino Biopharmaceutical, alongside potential regulatory and sales milestone payments exceeding $900 million. This strategic partnership aims to advance treatments for conditions such as asthma and atopic dermatitis.
For further insights into HK:1177 stock, check out TipRanks’ Stock Analysis page.